<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><description>独立报告、专业分析、深度解读</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 31 Mar 2021 13:23:28 +0800</pubDate><image><url>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</url><title>研发客研究院 | wechat-feeds</title><link>http://MzA5OTQyNjE3NA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>海和药物：专注小分子抗肿瘤新药 ｜SWOT分析</title><link>https://mp.weixin.qq.com/s/QEuDZ2ftuC_HdHeCTwxVVw</link><description></description><content:encoded><![CDATA[海和药物：专注小分子抗肿瘤新药 ｜SWOT分析]]></content:encoded><pubDate>Tue, 30 Mar 2021 20:50:33 +0800</pubDate></item><item><title>China Market Approval Tracker: Feb 2021</title><link>https://mp.weixin.qq.com/s/9rPLXf_bV_qLhlaGy9Kmrg</link><description></description><content:encoded><![CDATA[China Market Approval Tracker: Feb 2021]]></content:encoded><pubDate>Tue, 30 Mar 2021 09:15:52 +0800</pubDate></item><item><title>冠科美博：许可引进和授权合作双向开发 | SWOT分析</title><link>https://mp.weixin.qq.com/s/0jgi57jcVDLxSVm6WT2F0g</link><description></description><content:encoded><![CDATA[冠科美博：许可引进和授权合作双向开发 | SWOT分析]]></content:encoded><pubDate>Sun, 28 Mar 2021 13:27:57 +0800</pubDate></item><item><title>科济：CAR-T治疗实体瘤的机会与风险 | SWOT分析</title><link>https://mp.weixin.qq.com/s/Ml0NpDwtO3ZtRwJTE7FtZw</link><description></description><content:encoded><![CDATA[科济：CAR-T治疗实体瘤的机会与风险 | SWOT分析]]></content:encoded><pubDate>Thu, 25 Mar 2021 17:44:09 +0800</pubDate></item><item><title>Kintor&#39;s Cancer Drug Reduces COVID-19 Mortality Risk by 92%</title><link>https://mp.weixin.qq.com/s/1f0yGStkltphidjSBqGEdw</link><description></description><content:encoded><![CDATA[Kintor's Cancer Drug Reduces COVID-19 Mortality Risk by 92%]]></content:encoded><pubDate>Wed, 24 Mar 2021 09:25:27 +0800</pubDate></item><item><title>依生生物：能否靠皮卡平台开拓疫苗和肿瘤新疆域？ | SWOT分析</title><link>https://mp.weixin.qq.com/s/jqk4bM2s435Rj0JhxYehjA</link><description></description><content:encoded><![CDATA[依生生物：能否靠皮卡平台开拓疫苗和肿瘤新疆域？ | SWOT分析]]></content:encoded><pubDate>Mon, 22 Mar 2021 09:24:32 +0800</pubDate></item><item><title>天演药业：特有DPL平台助力研发与合作｜SWOT分析</title><link>https://mp.weixin.qq.com/s/GCI9TUt_IADGvKwLrhu7Fg</link><description></description><content:encoded><![CDATA[天演药业：特有DPL平台助力研发与合作｜SWOT分析]]></content:encoded><pubDate>Thu, 18 Mar 2021 17:21:30 +0800</pubDate></item><item><title>NewAmsterdam能让CETP抑制剂重燃希望吗？ | 前沿</title><link>https://mp.weixin.qq.com/s/xuhzg0DbZtlRb8wCYg8Mog</link><description></description><content:encoded><![CDATA[NewAmsterdam能让CETP抑制剂重燃希望吗？ | 前沿]]></content:encoded><pubDate>Wed, 17 Mar 2021 08:33:52 +0800</pubDate></item><item><title>卵巢癌维持治疗：PARP能否成为金标准？ | 分析</title><link>https://mp.weixin.qq.com/s/qn-j_4VQRLRJ5NNijnQnyA</link><description></description><content:encoded><![CDATA[卵巢癌维持治疗：PARP能否成为金标准？ | 分析]]></content:encoded><pubDate>Mon, 15 Mar 2021 09:31:09 +0800</pubDate></item><item><title>China Biotech Fundraising Tracker: Jan 2021</title><link>https://mp.weixin.qq.com/s/FoSD8pBin8HacD5-fD-05Q</link><description></description><content:encoded><![CDATA[China Biotech Fundraising Tracker: Jan 2021]]></content:encoded><pubDate>Fri, 12 Mar 2021 10:15:11 +0800</pubDate></item></channel></rss>